The regenerative medicine field includes some of the most rigorous and patient-centered physicians in musculoskeletal care. It also includes clinics that have attracted FDA warning letters, FTC enforcement actions, and federal court injunctions for marketing unapproved products, making false outcome claims, and delivering care outside the bounds of what evidence supports. Both exist in the same market, use similar terminology, and in some cases have similar-looking websites.
For patients, distinguishing between them requires knowing what to look for. The warning signs are specific and observable. This article describes them, explains why each matters, and then describes what transparent providers do differently, because the contrast is the clearest way to communicate what good looks like.
Why the Stem Cell Industry Requires Patient Skepticism
The Current Regulatory Landscape
The FDA regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under a framework that allows certain autologous, same-day procedures with minimally manipulated cells to be performed without the full investigational new drug approval process. This framework, established under Section 361 of the Public Health Service Act, has legitimate clinical applications and is used by responsible providers across the country.
However, this framework does not mean the field is unregulated. Clinics operating within this space must still comply with applicable good tissue practices, donor screening requirements, and processing standards. More importantly, procedures that go beyond minimal manipulation, use cells from sources other than the patient, or are applied in non-homologous uses require investigational approval that most commercial regenerative clinics do not hold.
Since 2018, the FDA has issued hundreds of warning letters to manufacturers and healthcare providers offering what the agency characterized as violative stem cell products. Federal courts have issued permanent injunctions against clinics found to be adulterating and misbranding stem cell products. The FTC has pursued clinics for deceptive marketing claims about stem cell products, obtaining permanent bans and financial relief in multiple cases. These enforcement actions represent documented cases where patient safety was compromised by providers operating outside appropriate standards.
The regulatory environment permits significant variation, and enforcement is imperfect. Patients cannot assume that an operating clinic has been vetted for safety or compliance. Patient skepticism, combined with the specific evaluation questions described below, is the most reliable protection available.
Why Bad Actors Persist in This Space
Several structural factors allow problematic clinics to continue operating. Patients who have exhausted conventional treatment options are often in a state of desperation or diminished hope, which makes them more receptive to claims that promise relief when nothing else has worked. This vulnerability is genuine and understandable, and it is routinely exploited by providers who prioritize revenue over clinical integrity.
Regenerative procedures are almost universally paid out of pocket, at prices that often range from several thousand to tens of thousands of dollars. This creates a significant financial incentive that some providers prioritize over evidence-based practice. Patients cannot easily verify clinical claims without technical knowledge they do not have. Marketing sophistication in this field often far exceeds the clinical substance behind it.
Regulatory enforcement is also slow relative to the pace of clinic operations. By the time a warning letter is issued, investigated, and acted upon, a clinic may have treated many patients. Patients who experience adverse outcomes often do not report them formally, so the data on harm is likely underrepresented relative to the actual frequency of problems.
Red Flags to Watch For
Guaranteed Outcomes and Cure Language
No medical procedure produces guaranteed outcomes. The human body’s response to any intervention, surgical, pharmacological, or biological, is influenced by factors that cannot be fully predicted or controlled. A physician who guarantees results, whether explicitly or through language that strongly implies certainty, is either misunderstanding the clinical evidence or deliberately overstating it to attract patients.
Watch for phrases like “guaranteed results,” “we cure arthritis,” “100% success rate,” or “you will be pain-free.” Also watch for subtler forms: claims that a procedure “always works for this condition,” testimonials framed as though they represent typical outcomes, or before-and-after photos shown without clinical context about patient selection, condition severity, or follow-up duration.
Appropriate language in regenerative medicine acknowledges the range of outcomes. Phrases like “many patients report improvement” or “research suggests benefit in this population” reflect honest clinical communication. This kind of qualified language is not weakness or hedging; it is accurate communication about how medicine works.
No Physician Involvement in the Consultation
A meaningful clinical assessment for a regenerative medicine procedure requires a physician. Determining whether a patient is an appropriate candidate for stem cell therapy or PRP involves reviewing imaging, understanding the patient’s full medical history, evaluating the severity and nature of the structural pathology, and considering whether other treatments should be tried first or alongside the regenerative approach.
This assessment cannot be delegated to a sales coordinator, a nurse who presents a scripted consultation, or an administrative staff member whose role is to convert inquiries into booked procedures. In clinics where this is the model, the physician may appear only on procedure day, after the patient has already committed financially. This arrangement prioritizes revenue capture over appropriate clinical care.
Ask directly who will conduct your consultation. If the answer is anyone other than the physician who will perform your procedure, that is a significant warning sign. Physician-led care means the physician is involved from the assessment through the treatment.
External Lab Processing with No Documentation
As discussed in an earlier article in this series, the processing model a clinic uses for cellular therapies has direct implications for cell quality and patient transparency. In itself, external laboratory processing is not an automatic disqualifier. Validated external labs with rigorous cold chain protocols and documented quality standards can operate responsibly.
The red flag is not external processing per se, but external processing combined with an inability or unwillingness to provide cell quality documentation. A clinic that sends cells to an external lab and receives a cell count and viability report for each patient, and then shares that report with the patient, is maintaining a meaningful level of transparency. A clinic that says “we use a top laboratory” but cannot show you a report for your specific sample on your specific procedure day is asking you to trust a chain you cannot verify.
If a clinic responds to questions about cell quality documentation with vague assurances rather than specific documentation, that is a red flag. The cells injected into your body should have a documented quality profile that you can review.
Pressure to Commit Before You Have Information
High-pressure sales tactics in a healthcare context are a serious warning sign. These appear in specific forms: phrases like “this price is only available today,” “we only have a few appointments left at this rate,” or “other patients in your situation are moving forward now.” All are urgency-generating language designed to push you toward a financial commitment before you have had time to evaluate your options.
They also appear in more subtle forms: discouraging questions by making them seem like obstacles, minimizing the time available for consent review, or presenting financial commitment as a necessary precursor to receiving the full clinical information you need to make a decision. Legitimate medical care does not require patients to commit financially before understanding what they are committing to.
Transparent providers actively support the time patients need to think, ask questions, and consider second opinions. If you express that you want to think about it, a reputable provider will encourage that rather than create pressure to decide immediately.
No Imaging Guidance During Procedures
For injections into joints, tendons, and other specific musculoskeletal structures, precise delivery matters enormously. Injecting adjacent to rather than within the target structure may mean the biological material reaches a location where it produces no clinical benefit, because the cells or growth factors are not in contact with the damaged tissue they are meant to address.
Imaging guidance, whether ultrasound for soft tissue and joint procedures or fluoroscopy for spinal and deeper structural procedures, allows the physician to confirm needle placement in real time before injection. This is a safety and efficacy feature, not an optional enhancement.
Clinics that perform “blind” or “landmark-guided” injections for procedures that require precision placement are cutting a corner that affects outcomes. Ask whether the clinic uses ultrasound or fluoroscopy guidance. Ask for which specific procedures they use each modality. If they do not have this equipment on-site, that is a meaningful quality gap.
What Reputable Clinics Do Instead
Honest Candidacy Assessment, Including Saying No
One of the most reliable markers of a trustworthy regenerative medicine clinic is their willingness to tell patients they are not good candidates. Every physician who practices long enough in any field develops the clinical experience to recognize when a treatment is unlikely to benefit a specific patient, and the professional obligation to communicate that honestly even when the conversation is financially inconvenient.
A clinic that accepts every patient who presents, regardless of condition severity, degree of structural damage, or the presence of factors that predict poor response, is prioritizing revenue over care. A clinic that turns patients away, refers some for orthopedic surgical evaluation, recommends different treatments when those treatments are more appropriate, and discusses alternatives alongside their own services is demonstrating clinical integrity.
When evaluating a clinic, pay attention to whether the physician asks questions that could lead to a “you are not a good candidate” conclusion. A physician who asks about the severity of your imaging findings, the duration and trajectory of your condition, your overall health status, and other factors that influence candidacy is performing an honest assessment. One who quickly confirms that you are a candidate without exploring these factors may be performing a sales process rather than a clinical evaluation.
Transparent Documentation Before and After Procedures
Reputable clinics provide documentation. Cell count and viability reports are generated and shared with patients before the procedure proceeds. Imaging guidance is documented in the procedure record. The consent process is thorough and unhurried, with time for questions. Follow-up appointments are built into the protocol, not offered as optional add-ons. Outcome tracking is systematic, using standardized measures that allow meaningful comparison over time.
After the procedure, medical records from the visit are complete and releasable to other providers. Patients receive clear instructions about post-procedure care, including activity restrictions, medication guidance (particularly around NSAIDs), and PT restart timing. The clinic is reachable if questions arise during recovery.
This level of documentation is not exceptional in medicine broadly; it is the standard of care. In regenerative medicine specifically, where the field’s credibility is still being established and patients must make high-stakes decisions in the absence of insurance coverage, this standard matters more, not less.
Clear Communication About What Is and Is Not Known
The evidence base for regenerative medicine is real and growing. Multiple randomized controlled trials support PRP for knee osteoarthritis, tendinopathy, and other musculoskeletal conditions. Stem cell research is producing promising results across a range of applications. But the field is also still developing, and honest providers communicate that nuance.
Reputable physicians distinguish between conditions where regenerative approaches have strong published evidence and conditions where the evidence is more preliminary. They acknowledge variation in outcomes. They do not present emerging applications as established ones. They discuss what happens if the treatment does not produce the desired result, including what additional options exist.
This kind of communication requires clinical confidence. A physician who is secure in their expertise and honest about the limits of that expertise is in a fundamentally different position than one who needs to project certainty to close a patient commitment. Patients who encounter the former are well-positioned to make genuinely informed decisions. Those who encounter the latter deserve better.
Sources
- Statement on stem cell clinic permanent injunction and FDA’s ongoing efforts to protect patients from risks of unapproved products (FDA)
- Harms Linked to Unapproved Stem Cell Interventions Highlight Need for Greater FDA Enforcement (Pew Charitable Trusts)
- Federal court issues decision holding that US Stem Cell clinics and owner adulterated and misbranded stem cell products (FDA)
- Statement by FDA Commissioner on FDA’s continued efforts to stop stem cell clinics from marketing unapproved products (FDA)
- On Patient Safety: Regenerative Medicine — The Hype Amplifies Safety Concerns (PMC)
- Putting Stem Cell-Based Therapies in Context (National Institutes of Health)
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.